Radionetics Oncology
Peter Chua is a seasoned professional in the field of chemistry with extensive experience in leadership roles across several biotechnology companies. Currently serving as Senior Director of Chemistry at Radionetics Oncology since September 2024, Peter previously held similar senior positions at Erasca, Inc. and Ignyta, Inc., where significant contributions to chemical research and development were made. Earlier career experiences include consulting and division management at The Centre for Drug Research and Development, as well as scientific roles at Cylene Pharmaceuticals, Merck, and Pfizer. Academically, Peter earned a Ph.D. in Synthetic Organic Chemistry from Université de Montréal, completed a Post Doctoral Fellowship at UC Irvine, and holds a B.Sc. in Chemistry and Business Administration from Simon Fraser University.
This person is not in any teams
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.